31 March 2023
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Investor Presentation
VENTURE LIFE GROUP PLC is pleased to announce that Jerry Randall (CEO) and Daniel Wells (CFO) will provide a live presentation relating to Final Results via the Investor Meet Company platform on Thursday 6 April 2023 at 4:00pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VENTURE LIFE GROUP PLC via:
https://www.investormeetcompany.com/venture-life-group-plc/register-investor
Investors who already follow VENTURE LIFE GROUP PLC on the Investor Meet Company platform will automatically be invited.
For further information, please contact:
| Venture Life Group PLC | +44 (0) 1344 578004 | ||
| Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer | | ||
|
Cenkos Securities plc (Nomad and Joint Broker) |
+44 (0) 20 7397 8900 | ||
| Michael Johnson/Russell Kerr (Sales) Stephen Keys/Camilla Hume (Corporate Finance) |
| ||
|
Singer Capital markets (Joint Broker) |
+44 (0) 20 7496 3000 | ||
| Jonathan Dighe (Sales) Shaun Dobson/Alaina Wong (Corporate Finance) |
| ||
|
| | ||
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.